Literature DB >> 33294984

Reduced plasmablast frequency is associated with seronegative myasthenia gravis.

Jeffrey T Guptill1,2, Richard Barfield3, Cliburn Chan3, Melissa A Russo1, Doug Emmett1, Shruti Raja1, Janice M Massey1, Vern C Juel1, Lisa D Hobson-Webb1, Karissa L Gable1, Natalia Gonzalez1, Alex Hammett2, James F Howard4, Manisha Chopra4, Henry J Kaminski5, Zaeem A Siddiqi6, Mattingly Migdal7, John S Yi8.   

Abstract

BACKGROUND: The immunopathology of autoimmune seronegative myasthenia gravis (SN MG) is poorly understood. Our objective was to determine immune profiles associated with a diagnosis of SN MG.
METHODS: We performed high-dimensional flow cytometry on blood samples from SN MG patients (N = 68), healthy controls (N = 46), and acetylcholine receptor antibody (AChR+) MG patients (N = 27). We compared 12 immune cell subsets in SN MG to controls using logistic modeling via a discovery-replication design. An exploratory analysis fit a multinomial model comparing AChR+ MG and controls to SN MG.
RESULTS: An increase in CD19+ CD20- CD38hi plasmablast frequencies was associated with lower odds of being a SN MG case in both the discovery and replication analyses (discovery P-value = .0003, replication P-value = .0021). Interleukin (IL) -21 producing helper T cell frequencies were associated with a diagnosis of AChR+ MG (P = .004).
CONCLUSIONS: Reduced plasmablast frequencies are strongly associated with a SN MG diagnosis and may be a useful diagnostic biomarker in the future.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  AChR; biomarkers; myasthenia gravis; plasmablasts; seronegative

Mesh:

Substances:

Year:  2020        PMID: 33294984      PMCID: PMC8100987          DOI: 10.1002/mus.27140

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  35 in total

Review 1.  Myasthenia Gravis.

Authors:  Nils E Gilhus
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

2.  Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection.

Authors:  Paola Cavalcante; Barbara Galbardi; Sara Franzi; Stefania Marcuzzo; Claudia Barzago; Silvia Bonanno; Giorgia Camera; Lorenzo Maggi; Dimos Kapetis; Francesca Andreetta; Amelia Biasiucci; Teresio Motta; Carmelo Giardina; Carlo Antozzi; Fulvio Baggi; Renato Mantegazza; Pia Bernasconi
Journal:  Immunobiology       Date:  2015-12-12       Impact factor: 3.144

3.  Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.

Authors:  Bin Zhang; John S Tzartos; Maria Belimezi; Samia Ragheb; Beverly Bealmear; Richard A Lewis; Wen-Cheng Xiong; Robert P Lisak; Socrates J Tzartos; Lin Mei
Journal:  Arch Neurol       Date:  2011-12-12

Review 4.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

Review 5.  Myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Authors:  Donald B Sanders; Jeffrey T Guptill
Journal:  Continuum (Minneap Minn)       Date:  2014-10

Review 6.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Authors:  A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

Review 7.  The role of IL-21 in regulating B-cell function in health and disease.

Authors:  Rachel Ettinger; Stefan Kuchen; Peter E Lipsky
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

8.  Augmentation of Circulating Follicular Helper T Cells and Their Impact on Autoreactive B Cells in Myasthenia Gravis.

Authors:  Cun-Jin Zhang; Ye Gong; Wenli Zhu; Yuan Qi; Chun-Sheng Yang; Ying Fu; Guoqiang Chang; Yujing Li; Samuel Shi; Kristofer Wood; Shafeeq Ladha; Fu-Dong Shi; Qiang Liu; Yaping Yan
Journal:  J Immunol       Date:  2016-08-19       Impact factor: 5.422

9.  Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis.

Authors:  Mina Hosseini; Behrouz Robat-Jazi; Vahid Shaygannejad; Shahriar Naffisi; Omid Mirmossayeb; Abbas Rezaei; Marjan Mansourian; Nafiseh Esmaeil
Journal:  Neuroimmunomodulation       Date:  2018-02-08       Impact factor: 2.492

10.  IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.

Authors:  Maria Isabel Leite; Saiju Jacob; Stuart Viegas; Judy Cossins; Linda Clover; B Paul Morgan; David Beeson; Nick Willcox; Angela Vincent
Journal:  Brain       Date:  2008-05-31       Impact factor: 13.501

View more
  1 in total

1.  Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Ivo Bozovic; Marina Peric; Ana Arsic Azanjac; Aleksa Palibrk; Ivana Bulatovic; Dejan Aleksic; Stojan Peric; Ivana Basta
Journal:  Qual Life Res       Date:  2021-04-08       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.